Table 2 Efficacy of a single oral dose of a novel chewable tablet (Simparica Trio™) containing sarolaner, moxidectin, and pyrantel pamoate against induced adult Ancylostoma caninum and adult Uncinaria stenocephala infections in dogs
Study | Species (isolate origin) | Stage at time of treatment | Day of inoculationa | Day of treatment | Day of worm recovery | Treatment groupb | n | No. of infected dogs | Worm count range | Geometric mean worm count | Efficacy compared to placebo | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
% Efficacy | Test statistic | |||||||||||
5 | A. caninum (Europe) | Adult | − 33 | 0 | 7 | Placebo | 8 | 8 | 59–136 | 109.9 | – | – |
Simparica Trio™ | 8 | 0 | 0 | 0.0 | 100% | t(7) = 47.61 P < 0.0001 | ||||||
6 | A. caninum (USA) | Adult | − 32 | Placebo | 8 | 8 | 9–46 | 22.7 | – | – | ||
Simparica Trio™ | 8 | 0 | 0 | 0.0 | 100% | t(7) = 20.55 P < 0.0001 | ||||||
7 | U. stenocephala (Europe) | Adult | − 32 | 0 | 7 | Placebo | 8 | 8 | 246–545 | 390.1 | – | – |
Simparica Trio™ | 8 | 0 | 0 | 0.0 | 100% | t(7) = 68.90 P < 0.0001 | ||||||
8 | U. stenocephala (Europe) | Adult | Placebo | 8 | 8 | 253–935 | 537.8 | – | – | |||
Simparica Trio™ | 8 | 0 | 0 | 0.0 | 100% | t(7) = 46.56 P < 0.0001 | ||||||